News

  • CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing

    This milestone payment is part of the PIAVE financing, amounting to a total of €6.7M and announced in November 2015. 

    Read the Press Release

    Read more
  • CROSSJECT receives authorization to conduct Zeneo® Midazolam bioequivalence study

    - Major milestone for the payment of the second tranche (€ 2.8M) of Bpifrance’s PIAVE financing to CROSSJECT
    - Significant competitive edge of Zeneo® in intramuscular injection on subjects having an epileptic seizure 

    Read the Press Release

    Read more

Events

  • 01/09/2017

    Crossject will be present at Biomed Event

    Crossject will be present at Biomed Event 2017 in Paris, on January 26th.
    Contact Tim Muller: tm@scientex.eu or  t.muller@crossject.com  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more
  • 01/08/2017

    Crossject will be present at ESN European Conferences 2017

    Crossject will be present at ESN Investors Conference in Paris, on March 30th 2017.
    Contact Tim Muller: tm@scientex.eu or t.muller@crossject.com  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more

video

Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos